3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 4
1
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Mycoses
1
Leukemia
1
Invasive Fungal Infections
1
Hematologic Neoplasms
1
Interventions
ceftolozane, tazobactam drug combination
2
Meropenem
2
Itraconazole
2
rasburicase
1
pegylated granulocyte colony-stimulating factor
1
pegaspargase
1
fludarabine phosphate
1
fludarabine
1
eltrombopag
1
drotrecogin alfa activated
1
dexamethasone 21-phosphate
1
Voriconazole
1
Vancomycin
1
Uric Acid
1
Urate Oxidase
1
Tropisetron
1
Teicoplanin
1
Solutions
1
Ribavirin
1
Pegloticase
1
Oxidoreductases
1
Ofloxacin
1
Micafungin
1
Metronidazole
1
Imatinib Mesylate
1
Hydromorphone
1
Human Papillomavirus Recombinant Vaccine nonavalent
1
Dexamethasone
1
Dasatinib
1
Ciprofloxacin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Hematologic Neoplasms
×
Voriconazole
×
Clear all
NCT01416025
2016-08-18
VoriTDM
Johns Hopkins University
Phase 4
Completed
29 enrolled
8 charts